Get started
Corcept Therapeutics IncorporatedCorcept Therapeutics IncorporatedCorcept Therapeutics Incorporated

Corcept Therapeutics Incorporated

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

CORT chart


Full chart

CORT upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪5.69 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
43.18
Basic EPS (TTM)
1.36 USD
Net income (FY)
‪105.50 M‬ USD
Revenue (FY)
‪482.38 M‬ USD
Shares float
‪90.20 M‬
Beta (1Y)
1.19

Employees


Employees (FY)
352
Change (1Y)
+53 +17.73%
Revenue / Employee (1Y)
‪1.37 M‬ USD
Net income / Employee (1Y)
‪299.70 K‬ USD

About Corcept Therapeutics Incorporated


Sector
Health Technology
CEO
Joseph K. Belanoff
Headquarters
Menlo Park
Website
corcept.com
Founded
1998
FIGI
BBG000BKJG33
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company. It engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

CORT news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of CORT is 59.60 USD — it has increased by 7.92% in the past 24 hours. Watch Corcept Therapeutics Incorporated stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Corcept Therapeutics Incorporated stocks are traded under the ticker CORT.
CORT stock has risen by 20.55% compared to the previous week, the month change is a 26.54% rise, over the last year Corcept Therapeutics Incorporated has showed a 130.38% increase.
We've gathered analysts' opinions on Corcept Therapeutics Incorporated future price: according to them, CORT price has a max estimate of 80.00 USD and a min estimate of 67.00 USD. Watch CORT chart and read a more detailed Corcept Therapeutics Incorporated stock forecast: see what analysts think of Corcept Therapeutics Incorporated and suggest that you do with its stocks.
CORT reached its all-time high on Oct 18, 2024 with the price of 50.07 USD, and its all-time low was 0.68 USD and was reached on Oct 12, 2006. View more price dynamics on CORT chart.
See other stocks reaching their highest and lowest prices.
CORT stock is 13.56% volatile and has beta coefficient of 1.19. Track Corcept Therapeutics Incorporated stock price on the chart and check out the list of the most volatile stocks — is Corcept Therapeutics Incorporated there?
Today Corcept Therapeutics Incorporated has the market capitalization of ‪6.24 B‬, it has decreased by −0.74% over the last week.
Yes, you can track Corcept Therapeutics Incorporated financials in yearly and quarterly reports right on TradingView.
Corcept Therapeutics Incorporated is going to release the next earnings report on Feb 12, 2025. Keep track of upcoming events with our Earnings Calendar.
CORT earnings for the last quarter are 0.41 USD per share, whereas the estimation was 0.28 USD resulting in a 45.42% surprise. The estimated earnings for the next quarter are 0.38 USD per share. See more details about Corcept Therapeutics Incorporated earnings.
Corcept Therapeutics Incorporated revenue for the last quarter amounts to ‪182.55 M‬ USD, despite the estimated figure of ‪171.97 M‬ USD. In the next quarter, revenue is expected to reach ‪198.04 M‬ USD.
CORT net income for the last quarter is ‪46.69 M‬ USD, while the quarter before that showed ‪35.12 M‬ USD of net income which accounts for 32.94% change. Track more Corcept Therapeutics Incorporated financial stats to get the full picture.
No, CORT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 9, 2024, the company has 352.00 employees. See our rating of the largest employees — is Corcept Therapeutics Incorporated on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Corcept Therapeutics Incorporated EBITDA is ‪144.81 M‬ USD, and current EBITDA margin is 22.46%. See more stats in Corcept Therapeutics Incorporated financial statements.
Like other stocks, CORT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Corcept Therapeutics Incorporated stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Corcept Therapeutics Incorporated technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Corcept Therapeutics Incorporated stock shows the strong buy signal. See more of Corcept Therapeutics Incorporated technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.